Publications by authors named "Inge Lefevre"

Claim this Profile
E
Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003) in Children With Prior Japanese Encephalitis or Yellow Fever Vaccination.
Chukiat Sirivichayakul, Shibadas Biswal, Xavier Saez-Llorens, Eduardo López-Medina, Charissa Borja-Tabora, Inge LeFevre

J Infect Dis· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of the dengue vaccine TAK-003 in an outbreak response: Modeling the Sri Lanka experience.
LakKumar Fernando, Randee Kastner, Pujitha Wickramasinghe, Asvini D Fernando, Dulanie Gunasekera, Inge LeFevre

PLoS Negl Trop Dis· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial.
Vianney Tricou, Delia Yu, Humberto Reynales, Shibadas Biswal, Xavier Saez-Llorens, Inge LeFevre

Lancet Glob Health· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consistency of immunogenicity in three consecutive lots of a tetravalent dengue vaccine candidate (TAK-003): A randomized placebo-controlled trial in US adults.
Vianney Tricou, Peter J Winkle, Leslie M Tharenos, Martina Rauscher, Ian Escudero, Inge LeFevre

Vaccine· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life.
Sanjay S Patel, Peter Winkle, Alice Faccin, Francesco Nordio, Inge LeFevre

Hum Vaccin Immunother· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults.
Inge LeFevre, Lulu Bravo, Nicolas Folschweiller, Eduardo Lopez Medina, Edson Duarte Moreira

NPJ Vaccines· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue.
Xavier Sáez-Llorens, Shibadas Biswal, Charissa Borja-Tabora, LakKumar Fernando, Mengya Liu, Inge LeFevre

Am J Trop Med Hyg· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study.
Vianney Tricou, Brandon Essink, John E Ervin, Mark Turner, Ian Escudero, Inge Lefevre

PLoS Negl Trop Dis· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country.
Vianney Tricou, Susannah Eyre, Mahadev Ramjee, Paul Collini, Zenaida Mojares, Inge Lefevre

Vaccine· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-year Efficacy and Safety of Takeda's Dengue Vaccine Candidate (TAK-003).
Luis Rivera, Shibadas Biswal, Xavier Sáez-Llorens, Humberto Reynales, Eduardo López-Medina, Inge LeFevre

Clin Infect Dis· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination.
Eduardo López-Medina, Shibadas Biswal, Xavier Saez-Llorens, Charissa Borja-Tabora, Lulu Bravo, Inge LeFevre

J Infect Dis· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City.
Shibadas Biswal, Jorge Fernando Mendez Galvan, Mercedes Macias Parra, Juan-Francisco Galan-Herrera, Monica Belisa Carrascal Rodriguez, Inge LeFevre

Rev Panam Salud Publica· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial.
Shibadas Biswal, Charissa Borja-Tabora, Luis Martinez Vargas, Hector Velásquez, Maria Theresa Alera, Inge LeFevre

Lancet· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial.
Vianney Tricou, Xavier Sáez-Llorens, Delia Yu, Luis Rivera, José Jimeno, Inge Lefevre

Lancet· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents.
Shibadas Biswal, Humberto Reynales, Xavier Saez-Llorens, Pio Lopez, Charissa Borja-Tabora, Inge LeFevre

N Engl J Med· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary and booster vaccination in Latin American children with a DTPw-HBV/Hib combination: a randomized controlled trial.
Felix Espinoza, Miguel Tregnaghi, Angela Gentile, Katia Abarca, Javier Casellas, Inge Lefevre

BMC Infect Dis· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity, reactogenicity and safety of three-dose primary and booster vaccination with combined diphtheria-tetanus-whole-cell pertussis-hepatitis B-reduced antigen content Haemophilus influenzae type b vaccine in Filipino children.
Salvacion R Gatchalian, Gunasekaran Ramakrishnan, Hans L Bock, Inge Lefevre, Jeanne M Jacquet

Hum Vaccin· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody persistence six years after two doses of combined hepatitis A and B vaccine.
Margaret A Burgess, Peter B McIntyre, Margaret Hellard, Tilman A Ruff, Inge Lefevre

Vaccine· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term immunogenicity of preservative-free hepatitis B vaccine formulations in adults.
Pierre Van Damme, Frank von Sonnenburg, Christoph Hatz, Bernard Hoet, Inge Lefevre

J Med Virol· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new DTPw-HBV/Hib vaccine: immune memory after primary vaccination and booster dosing in the second year of life.
Salvacion Gatchalian, Marietta Reyes, Nancy Bermal, Vijayalakshmi Chandrasekaran, Htay Htay Han, Inge Lefevre

Hum Vaccin· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Four is better than nine. a combined diphtheria-tetanus-pertussis-hepatitis B-Haemophilus influenzae type b vaccine for routine immunization in Malaysia.
Swee-Lan Wong, Padma Soosai, Yee-Leong Teoh, Htay-Htay Han, Inge Lefevre

Southeast Asian J Trop Med Public Health· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term antibody persistence in children primed and boosted with a DTPw-HBV vaccine at 2, 4, 6, 18, months of age.
Yong Poovorawan, Yanee Hutagalung, Voranush Chongsrisawat, Apiradee Thaemboonlers, Inge Lefevre

Vaccine· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The immunogenicity and reactogenicity of DTPw-HBV/Hib 2.5 combination vaccine: results from four phase III multicenter trials across three continents.
Eduardo Ortega-Barrìa, Güler Kanra, Geert Leroux, Lulu Bravo, Assad Safary, Inge Lefevre

Vaccine· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The immunogenicity and reactogenicity of a new DTPw-HBV vaccine as a primary and booster vaccination course in healthy infants.
Roman Prymula, Marie-Pierre David, Inge Lefevre, Igor Kohl, Mária Stefkovicová

Hum Vaccin· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new DTPw-HBV/Hib vaccine is immunogenic and safe when administered according to the EPI (Expanded Programme for Immunization) schedule and following hepatitis B vaccination at birth.
Salvacion Gatchalian, Marietta Reyes, Nancy Bernal, Inge Lefevre, Marie-Pierre David

Hum Vaccin· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis